Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Akoya Biosciences (NASDAQ: AKYA) announces its PhenoCycler-Fusion system has been selected as the primary spatial proteomics technology for a groundbreaking cancer research initiative by Team SAMBAI. The project, funded through Cancer Grand Challenges with up to $25 million, aims to create a first-of-its-kind Biobank and Data Repository for Cancer Equity Research.
The study will analyze 40,000 individuals of African descent from Africa, the UK, and the US, focusing on breast, pancreatic, and prostate cancers - which show disproportionately higher rates of aggressive tumor grade and early onset in the target population. Research teams from Johns Hopkins University, Nottingham University, Glasgow University, and King's College London will utilize the PhenoCycler-Fusion system to process thousands of samples.
The SAMBAI project (Societal, Ancestry, Molecular and Biological Analyses of Inequalities) aims to understand how genetics, biology, environmental, and social determinants contribute to cancer risk and outcomes in diverse populations.
Akoya Biosciences (NASDAQ: AKYA) annuncia che il suo sistema PhenoCycler-Fusion è stato selezionato come la principale tecnologia di proteomica spaziale per un'iniziativa di ricerca sul cancro innovativa condotta dal Team SAMBAI. Il progetto, finanziato attraverso il Cancer Grand Challenges con un massimo di 25 milioni di dollari, mira a creare una Biobanca e un Repository di Dati per la Ricerca sull'Equità nel Cancro, senza precedenti.
Lo studio analizzerà 40.000 individui di origine africana provenienti da Africa, Regno Unito e Stati Uniti, concentrandosi su tumori al seno, al pancreas e alla prostata - che mostrano tassi sproporzionatamente più elevati di gradi tumorali aggressivi e insorgenza precoce nella popolazione target. I team di ricerca dell'Università Johns Hopkins, dell'Università di Nottingham, dell'Università di Glasgow e del King's College di Londra utilizzeranno il sistema PhenoCycler-Fusion per elaborare migliaia di campioni.
Il progetto SAMBAI (Analisi Societale, Ancestrale, Molecolare e Biologica delle Disuguaglianze) ha l'obiettivo di comprendere come genetica, biologia, fattori ambientali e determinanti sociali contribuiscano al rischio di cancro e agli esiti in popolazioni diverse.
Akoya Biosciences (NASDAQ: AKYA) anuncia que su sistema PhenoCycler-Fusion ha sido seleccionado como la principal tecnología de proteómica espacial para una innovadora iniciativa de investigación sobre el cáncer dirigida por el Equipo SAMBAI. El proyecto, financiado a través de Cancer Grand Challenges con hasta 25 millones de dólares, tiene como objetivo crear una Biobanco y un Repositorio de Datos para la Investigación en Equidad del Cáncer, sin precedentes.
El estudio analizará 40,000 individuos de ascendencia africana de África, el Reino Unido y los Estados Unidos, centrándose en los cánceres de mama, páncreas y próstata, que muestran tasas desproporcionadamente más altas de grados tumorales agresivos y aparición temprana en la población objetivo. Los equipos de investigación de la Universidad Johns Hopkins, la Universidad de Nottingham, la Universidad de Glasgow y el King's College de Londres utilizarán el sistema PhenoCycler-Fusion para procesar miles de muestras.
El proyecto SAMBAI (Análisis Societal, Ancestral, Molecular y Biológico de las Desigualdades) tiene como objetivo comprender cómo la genética, la biología, los factores ambientales y los determinantes sociales contribuyen al riesgo de cáncer y a los resultados en poblaciones diversas.
Akoya Biosciences (NASDAQ: AKYA)는 PhenoCycler-Fusion 시스템이 SAMBAI 팀의 혁신적인 암 연구 이니셔티브를 위한 주요 공간 단백질체학 기술로 선택되었다고 발표했습니다. 이 프로젝트는 Cancer Grand Challenges를 통해 최대 2,500만 달러의 자금을 지원받아, 전례 없는 암 형평성 연구를 위한 바이오뱅크 및 데이터 저장소를 만드는 것을 목표로 하고 있습니다.
이 연구는 아프리카, 영국 및 미국 출신의 40,000명의 아프리카계 개인을 분석하며, 유방암, 췌장암 및 전립선암에 초점을 맞추고 있습니다. 이 암들은 목표 집단에서 공격적인 종양 등급과 조기 발병률이 불균형적으로 높습니다. Johns Hopkins 대학교, Nottingham 대학교, Glasgow 대학교 및 King's College London의 연구팀들은 수천 개의 샘플을 처리하기 위해 PhenoCycler-Fusion 시스템을 사용할 것입니다.
SAMBAI 프로젝트(불평등에 대한 사회적, 조상, 분자 및 생물학적 분석)는 유전학, 생물학, 환경 및 사회적 결정 요인이 다양한 인구에서 암 위험과 결과에 어떻게 기여하는지를 이해하는 것을 목표로 합니다.
Akoya Biosciences (NASDAQ: AKYA) annonce que son système PhenoCycler-Fusion a été sélectionné comme la principale technologie de protéomique spatiale pour une initiative de recherche sur le cancer révolutionnaire dirigée par l'équipe SAMBAI. Le projet, financé par Cancer Grand Challenges à hauteur de 25 millions de dollars, vise à créer une Biobanque et un Référentiel de Données pour la Recherche sur l'Équité en Matière de Cancer, sans précédent.
L'étude analysera 40 000 individus d'ascendance africaine provenant d'Afrique, du Royaume-Uni et des États-Unis, en se concentrant sur les cancers du sein, du pancréas et de la prostate - qui présentent des taux disproportionnés de grades tumoraux agressifs et d'apparition précoce dans la population cible. Les équipes de recherche de l'Université Johns Hopkins, de l'Université de Nottingham, de l'Université de Glasgow et du King's College de Londres utiliseront le système PhenoCycler-Fusion pour traiter des milliers d'échantillons.
Le projet SAMBAI (Analyses Sociétales, Ancestrales, Moléculaires et Biologiques des Inégalités) vise à comprendre comment la génétique, la biologie, les facteurs environnementaux et les déterminants sociaux contribuent au risque de cancer et aux résultats dans des populations diverses.
Akoya Biosciences (NASDAQ: AKYA) gibt bekannt, dass ihr PhenoCycler-Fusion-System als primäre Technologie für die räumliche Proteomik für eine bahnbrechende Krebsforschungsinitiative des Teams SAMBAI ausgewählt wurde. Das Projekt, das durch Cancer Grand Challenges mit bis zu 25 Millionen Dollar finanziert wird, zielt darauf ab, ein einzigartiges Biobank- und Datenrepository für die Krebsforschung zur Gleichheit zu schaffen.
Die Studie wird 40.000 Personen afrikanischer Abstammung aus Afrika, dem Vereinigten Königreich und den USA analysieren und sich auf Brust-, Bauchspeicheldrüsen- und Prostatakrebs konzentrieren - die in der Zielpopulation überproportional höhere Raten aggressiver Tumorgrade und frühzeitiger Erkrankung aufweisen. Forschungsteams von der Johns Hopkins University, der Universität Nottingham, der Universität Glasgow und dem King's College London werden das PhenoCycler-Fusion-System verwenden, um Tausende von Proben zu verarbeiten.
Das SAMBAI-Projekt (Gesellschaftliche, Ahnen-, Molekular- und Biologische Analysen von Ungleichheiten) hat zum Ziel, zu verstehen, wie Genetik, Biologie, Umwelt- und soziale Determinanten zum Krebsrisiko und zu den Ergebnissen in verschiedenen Bevölkerungsgruppen beitragen.
- Selected as primary technology provider for a major $25 million cancer research initiative
- Large-scale deployment of PhenoCycler-Fusion system across multiple prestigious research institutions
- Strategic positioning in high-growth cancer equity research market
- None.
Insights
Akoya's selection as the foundational technology for the SAMBAI initiative represents a significant validation of the company's PhenoCycler-Fusion platform in the competitive spatial biology market. The scale of this project is remarkable - processing samples from 40,000 individuals across three continents to study cancer disparities in populations of African descent.
This partnership with prestigious institutions including Johns Hopkins, Nottingham, Glasgow, and King's College London establishes Akoya as capable of supporting large-scale, multi-site research initiatives. The Cancer Grand Challenges funding of up to
What's particularly notable is the technical validation - the selection confirms that Akoya's platform offers the necessary high-plex capabilities and throughput required for processing thousands of samples across multiple cancer types. This positions the company's technology as suitable for population-scale studies that could influence both research and eventual clinical applications.
For a company with Akoya's current market cap (
Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative
The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples
MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research.
SAMBAI, which stands for “Societal, Ancestry, Molecular and Biological Analyses of Inequalities,” explains this team’s overarching objective to understand the mechanisms and contributions of genetics, biology, environmental, and social determinants to cancer risk and outcomes in diverse populations, and to provide foundational knowledge for developing novel approaches to reduce cancer inequities.
Team SAMBAI will focus on assessing disparate cancer outcomes in 40,000 individuals of African descent from Africa, the UK and the US and include proteomics, transcriptomics, and other data types. Teams from Johns Hopkins University, Nottingham University, Glasgow University, and King’s College London will run thousands of samples on the PhenoCycler-Fusion system using panels designed to study breast, pancreatic and prostate cancers – three cancers that have a disproportionately higher rate of aggressive tumor grade and early onset in the target population.
“We are excited that the PhenoCycler-Fusion is the spatial proteomics technology of choice for analyzing thousands of patient samples as part of this important initiative,” said Brian McKelligon, CEO of Akoya Biosciences. “A study of this size demands the high plex and high throughput of our solutions to generate data at the scale needed. We are honored to play a role in defining the factors that influence disparate outcomes in underserved populations.”
Cancer Grand Challenges identifies cancer’s toughest challenges and funds global research teams with the greatest potential to advance cancer research and improve outcomes for people affected by cancer. Team SAMBAI will receive up to
“As a leader in the spatial biology field, Akoya offers the best technology to assess the effect of environmental and societal factors on biology at the molecular level and on the development of cancer at the scale required for this project,” said Melissa Davis, PhD, Director of the Institute of Translational Genomic Medicine at Morehouse School of Medicine and leader of team SAMBAI. “For the first time in a large population, we plan to bring all of these factors together to understand their interconnectedness and contribution to disparities in health outcomes.”
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the potential of our products and services.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Media Contact:
Ritu Mihani
FAQ
What is the value of the Cancer Grand Challenges funding for Team SAMBAI's research using AKYA's technology?
How many patient samples will be analyzed using AKYA's PhenoCycler-Fusion system in the SAMBAI study?
Which types of cancer will be studied using AKYA's technology in the SAMBAI project?
Which research institutions will be using AKYA's PhenoCycler-Fusion system for the SAMBAI study?
What is the main purpose of using AKYA's PhenoCycler-Fusion in the SAMBAI cancer research project?
